83 related articles for article (PubMed ID: 6064867)
21. [A randomized in vivo trial of 3 factor VIII preparations].
Jacobsen L; Clausen C; Jans H; Gormsen J
Ugeskr Laeger; 1983 Mar; 145(10):739-42. PubMed ID: 6407165
[No Abstract] [Full Text] [Related]
22. Beriate-P study.
Gringeri A
Ann Hematol; 1994; 68 Suppl 3():S53-4. PubMed ID: 7910041
[No Abstract] [Full Text] [Related]
23. Hemophilia.
Aledort LM
N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
[No Abstract] [Full Text] [Related]
24. Standardization of factor VIII preparations.
Kasper CK; McDonald JD
N Engl J Med; 1973 Jan; 288(4):215. PubMed ID: 4682237
[No Abstract] [Full Text] [Related]
25. [Preparation and use of factor VIII concentrates in hemophilia].
Vilar JM; Ortega F; Martin-Arias DM; Vazquez J; Navarro JL
Sangre (Barc); 1969; 14(1):57-64. PubMed ID: 5792112
[No Abstract] [Full Text] [Related]
26. Hemophilia--a treatment in crisis.
Aledort LM; Hilgartner M; Lipton RA
N Engl J Med; 1988 Oct; 319(15):1017. PubMed ID: 3138539
[No Abstract] [Full Text] [Related]
27. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
Hilgartner MW
Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
[No Abstract] [Full Text] [Related]
28. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
29. Factor VIII inhibitor and severity of hemophilia.
Schoppmann A; Waytes AT
Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
[No Abstract] [Full Text] [Related]
30. Recombinant factor VIII in hemophilia.
Cohen A; Butler R
N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
[No Abstract] [Full Text] [Related]
31. [Acute and subacute intracranial hepatoma with hemophilia A--two cases report (author's transl)].
Toyama M; Ishikawa H; Ishii R; Okada K
No Shinkei Geka; 1978 Mar; 6(3):275-9. PubMed ID: 76995
[TBL] [Abstract][Full Text] [Related]
32. Report of the subcommittee on human factor VIII and factor IX preparations.
Brinkhous KM
Thromb Diath Haemorrh Suppl; 1968; 35():233. PubMed ID: 5761064
[No Abstract] [Full Text] [Related]
33. Hemophilia replacement therapy in developing countries: complementary approaches to the question of indigenous product manufacture versus importation.
Gellert GA
Thromb Haemost; 1996 Feb; 75(2):373-4. PubMed ID: 8815594
[No Abstract] [Full Text] [Related]
34. [Inhibitors suppression in hemophilia A with continued treatment of factor VIII].
Aznar JA; Jiménez C; García I; Martín G; Borrego D; Peiro A; Marty ML
Sangre (Barc); 1982; 27(4A):572. PubMed ID: 6818701
[No Abstract] [Full Text] [Related]
35. Hemostasis. II. The use of factor VIII concentrates in the therapy of hemophilia.
Davis RB
Nebr State Med J; 1971 Jun; 56(6):219-24. PubMed ID: 4253029
[No Abstract] [Full Text] [Related]
36. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
37. Lower doses of factor VIII for hemophilia.
Penner JA; Kelly PE
N Engl J Med; 1977 Aug; 297(7):401. PubMed ID: 876340
[No Abstract] [Full Text] [Related]
38. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
Stampfli K
Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
[No Abstract] [Full Text] [Related]
39. Factor products in the treatment of hemophilia.
Miller KL
J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
[No Abstract] [Full Text] [Related]
40. Letter: Commercial and NHS factor VIII concentrates.
Cash JD
Br Med J; 1976 Jan; 1(6003):221. PubMed ID: 1247788
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
